Gabapentin Tablet, Film Coated
Product Images NDC 50090-6855

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6855). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gabapentin Fig1)

An equation illustrating the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. The formula includes variables for age in years, weight in kilograms, and serum creatinine in mg/dL, with a multiplicative adjustment of 0.85 for females.*

FDA Label Image

Fig2 (Gabapentin Fig2)

Line chart showing weekly mean pain scores over 8 weeks in a study comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows the mean pain score. Gabapentin group shows a decreasing trend in pain scores, while placebo remains relatively stable.*

FDA Label Image

Fig3 (Gabapentin Fig3)

A line chart titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' depicting mean pain scores over a 7-week period. The x-axis is labeled 'Weeks' from Baseline to 7, and the y-axis is labeled 'Mean Pain Score' ranging from 0 to 10. The chart compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, showing trends during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Fig4 (Gabapentin Fig4)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates for gabapentin (GBP) at doses 1800 mg, 2400 mg, and 3600 mg versus placebo (PBO) in two separate studies. The chart shows higher response proportions for gabapentin groups relative to placebo, with significance indicators for p<0.01 and p<0.001.*

FDA Label Image

Fig5 (Gabapentin Fig5)

A scatter plot chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study.' It shows percentage differences on the vertical axis and daily gabapentin doses (mg) on the horizontal axis, including 600, 900, 1200, and 1800 mg. Three study groups are indicated by different markers: filled squares for STUDY a, open squares for STUDY b, and open rectangles for STUDY c. The plot presents dose-response data for gabapentin as adjunctive therapy in patients aged 12 or older with partial seizures.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin, showing a cyclohexane ring with amino and carboxymethyl functional groups attached.*

FDA Label Image

Label Image (Lbl500906855)

Gabapentin 600 mg film-coated oral tablets packaging label from A-S Medication Solutions. The label specifies the active ingredient Gabapentin, storage instructions at 68 to 77 degrees Fahrenheit with 90 tablets per carton, along with a QR code and product identification numbers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.